ClinicalTrials.gg
RecruitingNCT05487053Updated Apr 15, 2026

The Impact of Single-shot Adductor Canal Block Versus Continuous Femoral Nerve Block on Rehabilitation After Total Knee Replacement

An interventional study of Single-shot adductor canal block and Continuous femoral nerve block in Osteo Arthritis Knee and Gonarthrosis, sponsored by Negovsky Reanimatology Research Institute. Recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Negovsky Reanimatology Research Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Total knee replacement (TKR) is considered the most effective and safe method of radical treatment of late stages of knee osteoarthritis. A well-known problem of TKR is a severe postoperative pain syndrome, which is observed in more than 50% of patients.

Femoral nerve block (FNB) is the "gold standard" for continuous postoperative analgesia after total knee replacement, as it is effective in reducing the frequency of use of opioid analgetics and reduce the duration of hospitalization. At the same time, the negative effect of this method is the motor blockade of the quadriceps femoris muscle which leads to functional impairment and is associated with an increased risk of falling.

Adductor canal block (ACB) provides adequate analgesia comparable to femoral nerve block. Moreover, ACB doesn't affect the motor function of the quadriceps femoris muscle.

The possibility of enhanced recovery after total knee replacement is the reason to compare single-shot adductor canal block and continuous femoral nerve block.

02

Conditions studied

  • Osteo Arthritis Knee
  • Gonarthrosis

Keywords

  • Osteo Arthritis Knee
  • Gonarthrosis
  • Regional anesthesia
  • Analgesia
  • Postoperative analgesia
  • Total knee replacement
  • Continuous femoral nerve block
  • Femoral nerve block
  • Continuous adductor canal block
  • Adductor canal block
03

In context

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's planned enrollment of 220 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Negovsky Reanimatology Research Institute is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18
  • Planned primary total knee replacement
  • Planned neuraxial anesthesia
  • Written

Exclusion criteria

Exclusion Criteria:

  • Urgent surgery
  • Planned revision total knee replacement
  • Known allergic reaction to anesthetics
  • Confirmed localized infection at the puncture sites
  • Confirmed localized tumor at the puncture sites
  • Peripheral neuropathy of the lower extremities
  • Parkinson's disease
  • Previously enrolled in this trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Single-shot adductor canal block

    Procedure: Single-shot adductor canal block

  • Active comparator
    Continuous femoral nerve block

    Procedure: Continuous femoral nerve block

Interventions

  • ProcedureSingle-shot adductor canal block

    Postoperative analgesia in this group will be carried out by a single-shot bolus of 20 ml Ropivacaine 0.5% in the region of the middle third of the adductor canal.

  • ProcedureContinuous femoral nerve block

    Postoperative analgesia in this group will be carried out by continuous infusion of local anesthetics through a catheter installed to the femoral nerve in the area of the femoral triangle. Ropivacaine 0.2% solution will be used for postoperative analgesia. Local anesthetic infusion rate is 4 ml/h to 10 ml/h.

06

What researchers measure

Primary outcomes

  1. Ambulation distance

    Less meters means worse outcome

    Time frame: postoperative day 1

Secondary outcomes

  1. Ambulation distance

    Less meters means worse outcome

    Time frame: postoperative day 2

  2. Timed up and go test

    More seconds means worse outcome

    Time frame: postoperative day 1

  3. Timed up and go test

    More seconds means worse outcome

    Time frame: postoperative day 2

  4. 10 meters walk test

    More seconds means worse outcome

    Time frame: postoperative day 1

  5. 10 meters walk test

    More seconds means worse outcome

    Time frame: postoperative day 2

  6. 30 seconds chair stand test

    Less exercise done means worse outcome

    Time frame: postoperative day 1

  7. 30 seconds chair stand test

    Less exercise done means worse outcome

    Time frame: postoperative day 2

  8. 5 times sit to stand test

    More seconds means worse outcome

    Time frame: postoperative day 1

  9. 5 times sit to stand test

    More seconds means worse outcome

    Time frame: postoperative day 2

  10. time to readiness to dicharge

    time from the day of surgery to the day of readiness to discharge

    Time frame: 30 day

  11. length of hospitalization

    time from the day of surgery to the day of discharge

    Time frame: 30 day

Other outcomes

  1. intravascular local anesthetic injection

    frequency of intravascular local anesthetic injection

    Time frame: 30 day

  2. neuropathy after the procedure

    frequency of neuropathy after the procedure

    Time frame: 30 day

07

Study locations

1 of 1 sites recruiting
  • Clinical Hospital on Yauza
    Moscow, 111033, Russia
    Recruiting
    • Levan Berikashvili, PhD · Contactlb.berikashvili@gmail.com · +79263308968
    • Levan Berikashvili, PhD · Principal investigator
    • Sergey Stepanenko · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2027, 45 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 45 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2022
First posted
Aug 4, 2022
StartActual
Feb 3, 2024
Primary completionEst.
Dec 1, 2027
CompletionEst.
Jul 1, 2028
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05487053
Lead sponsor
Negovsky Reanimatology Research Institute
Responsible party
Valery Likhvantsev, MD (Head of the Research V. Negovsky Reanimatology Research Institute, Negovsky Reanimatology Research Institute) — Principal investigator
First posted
Aug 4, 2022
Start date
Feb 3, 2024
Primary completion
Dec 1, 2027 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Apr 15, 2026

Study contacts

Valery Likhvantsev
Contact
lik0704@gmail.com
+79036235982
Levan Berikashvili
Contact
levan.berikashvili@mail.ru
+79263308968
Valery Likhvantsev
principal investigator · Negovsky Reanimatology Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion